2023-05-30 09:30:13 ET
T2 Biosystems ( NASDAQ: TTOO ) stock price scales 31% with the second largest sale of sepsis-driven T2Dx instruments in company history.
Its distribution partner, Biomedica Poland, secured a multi-year contract for T2Dx instruments and sepsis test panels that are expected to be deployed in selected hospitals across Poland.
The initial order includes seven T2Dx Instruments, valued at more than $450,000, with the potential for nine additional instruments to be sold and deployed into an increased number of hospitals in Poland during H2 2023.
The initial term of the contract is 3 years, with the potential to extend for an additional 2 years.
For further details see:
T2 Biosystems up 31%, gets second largest order for sepsis-driven instrument